Gufic Biosciences (BOM:509079) Scaled Net Operating Assets: N/A (As of Mar. 2026)


BOM:509079 Gufic Biosciences Ltd BOM:509079
75 GF Score
Price ₹387.10
GF Value ₹408.46
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Gufic Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gufic Biosciences's operating assets for the quarter that ended in Mar. 2026 was ₹12,662 Mil. Gufic Biosciences's operating liabilities for the quarter that ended in Mar. 2026 was ₹2,726 Mil. Gufic Biosciences's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Gufic Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Gufic Biosciences Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Scaled Net Operating Assets Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 1.25 1.00 0.84 0.85

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:509079 vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Scaled Net Operating Assets falls into.


BOM:509079
75GF Score
Gufic Biosciences Ltd BOM:509079
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gufic Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(12661.57-2726.34)/11693.637
=0.85

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=13423.74 - 762.17
=12661.57

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6773.873 - 1194.085 - 2853.448
=2726.34

Gufic Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(12661.57-2726.34)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=13423.74 - 762.17
=12661.57

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6773.873 - 1194.085 - 2853.448
=2726.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹387.10 is trading 5.2% below its estimated GF Value™ of ₹408.46. GuruFocus considers Gufic Biosciences to be Fairly Valued.

Key valuation signals for BOM:509079:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹408.46 vs. price of ₹387.10 (5.2% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
75GF Score

Get the complete analysis for BOM:509079

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹387.10
Price
₹408.46
GF Value